Exicure, Inc. (NASDAQ:XCUR) Short Interest Update

Exicure, Inc. (NASDAQ:XCUR) was the recipient of a large drop in short interest in June. As of June 30th, there was short interest totaling 6,731 shares, a drop of 54.4% from the June 15th total of 14,757 shares. Based on an average trading volume of 70,886 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.2% of the company’s stock are short sold.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings downgraded shares of Exicure from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, June 11th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Exicure Stock Down 5.7%

NASDAQ:XCUR opened at $1.65 on Tuesday. The company has a market capitalization of $10.51 million, a PE ratio of -1.06 and a beta of 3.61. Exicure has a 52-week low of $1.65 and a 52-week high of $9.50. The stock’s 50 day moving average price is $2.67 and its 200 day moving average price is $3.86.

Exicure (NASDAQ:XCUR) last issued its quarterly earnings data on Friday, May 29th. The company reported ($0.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($18.60) by $18.31.

Exicure Company Profile

Exicure is a clinical‐stage biotechnology company pioneering the development of next‐generation genetic medicines through its proprietary spherical nucleic acid (SNA) delivery platform. This nanotechnology‐based approach is designed to facilitate the intracellular delivery of oligonucleotide therapeutics, addressing longstanding challenges in targeting hard‐to‐reach tissues such as the central nervous system.

The company’s pipeline encompasses programs for neurological disorders—including Huntington’s disease, Parkinson’s disease and Alzheimer’s disease—as well as exploratory efforts in dermatological indications and oncology.